Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Head & Neck 2Gastrointestinal 2Genitourinary 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 78Carcinoma, Non-Small-Cell Lung 16Oropharyngeal Neoplasms 13Mouth Neoplasms 11Carcinoma, Squamous Cell 11Thyroid Carcinoma, Anaplastic 10Neoplasm Metastasis 10Thyroid Neoplasms 9Salivary Gland Neoplasms 9Recurrence 9Hypopharyngeal Neoplasms 9Carcinoma 9Neoplasms 8Nasopharyngeal Neoplasms 8Nasopharyngeal Carcinoma 8Melanoma 8Laryngeal Neoplasms 8Ovarian Neoplasms 7Lung Neoplasms 7Breast Neoplasms 7Endometrial Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Colorectal Neoplasms 5Small Cell Lung Carcinoma 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Ovarian Epithelial 4Tongue Neoplasms 3

Interventions

Cisplatin 4pembrolizumab 3selpercatinib 2pralsetinib 2Pemetrexed 2Paclitaxel 2Fulvestrant 2Carboplatin 2trametinib 1ribociclib 1repotrectinib 1patritumab 1palbociclib 1golotimod 1exemestane 1dabrafenib 1cobimetinib 1alectinib 1abemaciclib 1Vemurafenib 1Taxes 1Tamoxifen 1STX-478 1Radiotherapy, Intensity-Modulated 1Nimorazole 1Metformin 1Letrozole 1Imlunestrant 1Gemcitabine 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × Paclitaxel × Head & Neck × Clear all
NCT04222972 2026-03-05

AcceleRET-Lung

Hoffmann-La Roche

Phase 3 Terminated
223 enrolled 18 charts
Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡